

Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/Verified
Infliximab Neutralizing Antibody Titer	1:355			18-256-900133	13-Sep-18 13:46:00	13-Sep-18 13:47:00	13-Sep-18 13:58:02
Infliximab Activity w/Rflx to Ab	Not Detected			18-256-900133	13-Sep-18 13:46:00	13-Sep-18 13:47:00	13-Sep-18 13:52:46
EER IFX Rflx to Neutralizing Ab Conf.	See Note f			18-256-900133	13-Sep-18 13:46:00	13-Sep-18 13:47:00	13-Sep-18 13:58:02
EER Infliximab Activity w/Rflx to Ab	See Note f			18-256-900133	13-Sep-18 13:46:00	13-Sep-18 13:47:00	13-Sep-18 13:52:46

13-Sep-18 13:46:00 EER IFX Rflx to Neutralizing Ab Conf.:
 Access ARUP Enhanced Report using either link below:

-Direct access: [REDACTED]

-Enter Username, Password: [REDACTED]

Username: [REDACTED]
 Password: [REDACTED]

13-Sep-18 13:46:00 EER Infliximab Activity w/Rflx to Ab:
 Access ARUP Enhanced Report using either link below:

-Direct access: [REDACTED]

-Enter Username, Password: [REDACTED]

Username: [REDACTED]
 Password: [REDACTED]

13-Sep-18 13:46:00 Infliximab Activity w/Rflx to Ab:
 INTERPRETIVE INFORMATION: Infliximab or biosimilar w/Rflx to NAb

This test measures the capacity of infliximab to neutralize TNF-alpha activity. If infliximab is not detected, testing for neutralizing antibodies (NAb) will be performed. Infliximab NAb titer is obtained by identifying the minimal serum dilution at which blocking of infliximab activity is no longer observed.

This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

Infliximab Activity	Infliximab Neutralizing Ab. Titer	Interpretation
Not Detected	Not Detected	A higher dosage of infliximab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL	N/A	A change to another type of

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

or greater

therapy (not targeting TNF-
alpha) may be appropriate, if
the patient did not respond
adequately to infliximab
therapy.

Test developed and characteristics determined by ARUP Laboratories. See Compliance
Statement B: aruplab.com/CS